Advertisement
Canada markets closed

  • S&P/TSX

    22,116.69
    -152.41 (-0.68%)
     

  • S&P 500

    5,283.40
    +5.89 (+0.11%)
     

  • DOW

    38,571.03
    -115.27 (-0.30%)
     

  • CAD/USD

    0.7333
    -0.0006 (-0.08%)
     

  • CRUDE OIL

    73.72
    -0.50 (-0.67%)
     

  • Bitcoin CAD

    94,377.42
    +1,117.87 (+1.20%)
     

  • CMC Crypto 200

    1,449.09
    -18.85 (-1.28%)
     

  • GOLD FUTURES

    2,364.80
    -4.50 (-0.19%)
     

  • RUSSELL 2000

    2,059.68
    -10.45 (-0.50%)
     

  • 10-Yr Bond

    4.4020
    -0.1120 (-2.48%)
     

  • NASDAQ futures

    18,649.00
    +2.75 (+0.01%)
     

  • VOLATILITY

    13.11
    +0.19 (+1.47%)
     

  • FTSE

    8,262.75
    -12.63 (-0.15%)
     

  • NIKKEI 225

    38,749.25
    -173.78 (-0.45%)
     

  • CAD/EUR

    0.6719
    -0.0008 (-0.12%)
     

Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

Pacira BioSciences
·1 min read
Pacira BioSciences
Pacira BioSciences

TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference at 10:30 AM ET on Tuesday, May 14, 2024 in New York. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

About Pacira

Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

CONTACT: Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 Christian.pedetti@pacira.com